Sarepta Therapeutics Inc. (NASDAQ: SRPT) Stock Upgraded at Cowen and Company

Analysts at Cowen and Company upgraded shares of Sarepta Therapeutics Inc. (NASDAQ: SRPT) from Market Perform to Outperform today. The company currently has a rating of Outperform on the shares. The one-year price target of $44.46 is a decrease compared to the opening price of $52.02, causing a fair amount of other analysts to comment on the stock recently. Looking back over the last year, Sarepta Therapeutics Inc. stock has a high of $56.80. Stock prices often move to the upside on recommendations and new price targets of professional analysts.

U.S. stocks closed higher Tuesday as investors anticipate the results of meetings from the Federal Reserve and the Bank of Japan.

The Dow Jones Industrial Average DJIA, +0.05% rose 9.79 points, or less than 0.1%, to close at 18,129.96.

The S&P 500 index SPX, +0.03% advanced 0.64 points to finish at 2,139.76, led by gains in the health-care and consumer-staples sectors.

The Nasdaq Composite index COMP, +0.12% gained 6.33 points, or 0.1%, to close at 5,241.35.

Yesterday Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares last traded at $55.73, which represents a jump of $6.79 over the previous closing price. Opening at $52.02, they ranged from $51.95 and $56.80 throughout the day.

Sarepta Therapeutics Inc. (NASDAQ: SRPT) now has a market cap of 2.67B.

21,126,825 shares traded hands yesterday, 95 percent above the average, out of a total float 40,605,000. Considerable volume accumulation by institutional investors may be in the near future as the combination of substantial gains in trading volume and price inflation can be deciding factors.

As with all potential breakouts, investors look for volume to be at least 40%-50% greater than normal on the breakout to demonstrate that fund managers and other professional investors are jumping in.

Institutional sponsorship is defined by ownership of a stock by mutual funds, banks, pension funds and other large institutions.

Professional investors such as these retain teams of analysts researching thousands of stocks, so it is good validation to see them taking a postion in a stock you’re considering.

By following the activity of these professional investors—and the moving averages they influence— traders are able to make make smarter trades.

With that in mind, Sarepta Therapeutics Inc. (NASDAQ: SRPT) now has a 50-day MA of $28.17 and 200-day MA of $21.37. It has traded in a 52-week range between $8.00 – 56.80 and today’s last price is 0.02% lower than the 52 week high of $56.80.

Indeed, earnings growth is among the most critical things to look at in regards to stock investing and, accordingly, investors identify companies that have been successful at growing their earnings at least 25% or more over the past 3 years.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of the website. Readers should not consider statements made by the author as formal recommendations and should consult their financial adviser before making any investment decisions. To read our full disclosure, please see our terms and conditions page.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.